Bg pattern

COMIRNATY ORIGINAL/OMICRON BA.4-5 (15/15 MICROGRAMS)/DISPERSIBLE INJECTABLE DOSE

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use COMIRNATY ORIGINAL/OMICRON BA.4-5 (15/15 MICROGRAMS)/DISPERSIBLE INJECTABLE DOSE

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the User

Comirnaty Original/Omicron BA.4-5 (15/15 micrograms)/dispersion for injection

Adults and adolescents from 12 years of age

COVID-19 mRNA vaccine (with modified nucleosides)

tozinameran/famtozinameran

This medicine is subject to additional monitoring, which will allow for quick identification of new safety information. You can help by reporting any side effects you may get. The last section of this leaflet includes information on how to report side effects.

Read all of this leaflet carefully before you receive this vaccine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor, pharmacist, or nurse.
  • If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack

  1. What is Comirnaty Original/Omicron BA.4-5 and what is it used for
  2. What you need to know before you receive Comirnaty Original/Omicron BA.4-5
  3. How Comirnaty Original/Omicron BA.4-5 is given
  4. Possible side effects
  5. Storage of Comirnaty Original/Omicron BA.4-5
  6. Contents of the pack and other information

1. What is Comirnaty Original/Omicron BA.4-5 and what is it used for

Comirnaty Original/Omicron BA.4-5 is a vaccine used to prevent COVID-19 caused by the SARS-CoV-2 virus. It is given to adults and adolescents from 12 years of age.

Comirnaty Original/Omicron BA.4-5 is only indicated in individuals who have previously received at least one primary vaccination schedule against COVID-19.

The vaccine makes the immune system (the body's natural defenses) produce antibodies and blood cells that fight the virus, providing protection against COVID-19.

Because Comirnaty Original/Omicron BA.4-5 does not contain the virus to produce immunity, it cannot give you COVID-19.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you receive Comirnaty Original/Omicron BA.4-5

Comirnaty Original/Omicron BA.4-5 must not be given

  • if you are allergic to the active substance or to any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Talk to your doctor, pharmacist, or nurse before you receive the vaccine if:

  • you have ever had a severe allergic reaction or breathing problems after being given any other vaccine or after you were given Comirnaty or Comirnaty Original/Omicron BA.4-5 in the past;
  • you are nervous about the vaccination process or have fainted after an injection with a needle;
  • you have a severe illness or infection with a high fever. However, you can be vaccinated if you have a mild fever or an upper respiratory tract infection such as a cold;
  • you have a bleeding problem, bruise easily, or are taking a medicine to prevent blood clotting;
  • you have a weakened immune system due to a disease such as HIV or due to a medicine, such as corticosteroids, that affects the immune system.

There is an increased risk of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the outer lining of the heart) after vaccination with Comirnaty (see section 4). These conditions can occur within a few days of vaccination and have mainly occurred within 14 days. They have been observed more frequently after the second dose of vaccination and more frequently in young males. The risk of myocarditis and pericarditis appears to be lower in children between 5 and 11 years of age than in those between 12 and 17 years of age. After vaccination, you should be alert to the signs of myocarditis and pericarditis, such as difficulty breathing, palpitations, and chest pain, and should seek immediate medical attention if they occur.

As with any vaccine, Comirnaty Original/Omicron BA.4-5 may not fully protect all people who receive it, and it is not known how long you will be protected.

The efficacy of Comirnaty Original/Omicron BA.4-5 may be lower in immunocompromised individuals. In these cases, you should continue to maintain physical precautions to help prevent COVID-19. Additionally, your close contacts should be vaccinated as appropriate. Discuss individual recommendations with your doctor.

Children

Comirnaty Original/Omicron BA.4-5 (15/15 micrograms)/dispersion for injection is not recommended for use in children under 12 years of age.

A pediatric presentation is available for children between 5 and 11 years of age. For more information, see the package leaflet for Comirnaty Original/Omicron BA.4-5 (5/5 micrograms)/concentrate for dispersion for injection.

Other medicines and Comirnaty Original/Omicron BA.4-5

Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicine or have recently received any other vaccine.

Pregnancy and breastfeeding

If you are pregnant or think you might be pregnant, tell your doctor, nurse, or pharmacist before you receive this vaccine.

There are no available data on the use of Comirnaty Original/Omicron BA.4-5 during pregnancy. However, a large amount of information on pregnant women vaccinated with the initially approved Comirnaty vaccine during the second and third trimesters has not shown negative effects on pregnancy or on the newborn. Although information on the effects on pregnancy or the newborn after vaccination during the first trimester is limited, no change in the risk of spontaneous abortion has been observed. Comirnaty Original/Omicron BA.4-5 can be used during pregnancy.

There are no available data on the use of Comirnaty Original/Omicron BA.4-5 during breastfeeding. However, no effects on the newborn/infant are expected. Data on women who were breastfeeding after vaccination with the initially approved Comirnaty vaccine have not shown a risk of adverse effects in breastfed children. Comirnaty Original/Omicron BA.4-5 can be used during breastfeeding.

Driving and using machines

Some of the effects of vaccination mentioned in section 4 (Possible side effects) may temporarily affect your ability to drive or use machines. Wait until these effects have gone before you drive or use machines.

3. How Comirnaty Original/Omicron BA.4-5 is given

Comirnaty Original/Omicron BA.4-5 is given as an injection of 0.3 ml into a muscle in the arm.

Comirnaty Original/Omicron BA.4-5 can be given at least 3 months after the most recent dose of a COVID-19 vaccine.

Comirnaty Original/Omicron BA.4-5 is only indicated in individuals who have previously received at least one primary vaccination schedule against COVID-19.

Talk to your healthcare professional about eligibility for the booster dose and when to administer it.

For detailed information on the primary vaccination schedule in individuals 12 years of age and older, see the package leaflet for Comirnaty 30 micrograms/dispersion for injection or Comirnaty 30 micrograms/concentrate for dispersion for injection.

If you have any further questions on the use of Comirnaty Original/Omicron BA.4-5, ask your doctor, pharmacist, or nurse.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all vaccines, Comirnaty Original/Omicron BA.4-5 can cause side effects, although not everybody gets them.

Very common side effects:may affect more than 1 in 10 people

  • injection site: pain, swelling
  • fatigue
  • headache
  • muscle pain
  • chills
  • joint pain
  • diarrhea
  • fever

Some of these side effects were slightly more frequent in adolescents between 12 and 15 years of age than in adults.

Common side effects:may affect up to 1 in 10 people

  • redness at the injection site
  • nausea
  • vomiting

Uncommon side effects:may affect up to 1 in 100 people

  • enlarged lymph nodes (more frequently observed after the booster dose)
  • malaise
  • arm pain
  • insomnia
  • itching at the injection site
  • allergic reactions such as skin rash or itching
  • feeling weak or lack of energy/drowsiness
  • decreased appetite
  • dizziness
  • excessive sweating
  • night sweats

Rare side effects:may affect up to 1 in 1,000 people

  • temporary paralysis of one side of the face
  • allergic reactions such as hives or swelling of the face

Very rare side effects:may affect up to 1 in 10,000 people

  • inflammation of the heart muscle (myocarditis) or inflammation of the outer lining of the heart (pericarditis) that can lead to difficulty breathing, palpitations, or chest pain

Frequency not known(cannot be estimated from the available data)

  • severe allergic reaction
  • extensive swelling of the limb where the vaccine was administered
  • swelling of the face (may occur in patients who have received dermal filler injections)
  • a skin reaction that causes red spots or patches on the skin, which may look like a target or a "bull's-eye" with a dark red center surrounded by lighter red rings (erythema multiforme)
  • abnormal sensation in the skin, such as tingling or prickling (paresthesia)
  • decreased sensitivity, especially in the skin (hypoesthesia)
  • heavy menstrual bleeding (most cases do not appear to be serious and are temporary)

Reporting of side effects

If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if it is possible side effects not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V and include the batch number if available. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Comirnaty Original/Omicron BA.4-5

Keep this medicine out of the sight and reach of children.

The following information on storage, expiry, and handling is intended for healthcare professionals.

Do not use this medicine after the expiry date which is stated on the carton and on the label after EXP. The expiry date is the last day of the month shown.

Store in a freezer at –90 °C to –60 °C.

Store in the original package to protect from light.

The vaccine will be received frozen at –90 °C to –60 °C. The frozen vaccine can be stored at –90 °C to –60 °C or at 2 °C to 8 °C after receipt.

Single-dose vials: If stored frozen at –90 °C to –60 °C, the packs of 10 single-dose vials of the vaccine can be thawed at 2 °C to 8 °C for 2 hours or individual vials can be thawed at room temperature (up to 30 °C) for 30 minutes.

Multidose vials: If stored frozen at –90 °C to –60 °C, the packs of 10 multidose vials of the vaccine can be thawed at 2 °C to 8 °C for 6 hours or individual vials can be thawed at room temperature (up to 30 °C) for 30 minutes.

Frozen vials: Once removed from the freezer, the unopened vial can be stored and transported refrigerated at 2 °C to 8 °C for a maximum of 10 weeks; do not exceed the expiry date printed (EXP). The outer packaging should be marked with the new expiry date at 2 °C to 8 °C. Once thawed, the vaccine cannot be re-frozen.

Before use, unopened vials can be stored for a maximum of 12 hours at temperatures between 8 °C and 30 °C.

Thawed vials can be handled in ambient light conditions.

Opened vials: After the first puncture, store the vaccine at 2 °C to 30 °C and use within 12 hours, which includes a transport time of up to 6 hours. Discard unused vaccine.

Do not use this vaccine if you notice visible particles or a change in color.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.

6. Container Contents and Additional Information

Comirnaty Original/Omicron BA.4-5 Composition

  • The active ingredients of the COVID-19 mRNA vaccine are tozinameran and famtozinameran.
    • A single-dose vial contains 1 dose of 0.3 ml with 15 micrograms of tozinameran and 15 micrograms of famtozinameran (Omicron BA.4-5) per dose.
    • A multi-dose vial contains 6 doses of 0.3 ml with 15 micrograms of tozinameran (Original) and 15 micrograms of famtozinameran (Omicron BA.4-5) per dose.
  • The other components are:
    • ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315)
    • 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159)
    • 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)
    • cholesterol
    • tromethamine
    • tromethamine hydrochloride
    • sucrose
    • water for injectable preparations

Product Appearance and Container Contents

The vaccine is a dispersion (pH: 6.9-7.9) of a color between white and off-white that is presented in:

  • A single-dose vial of 1 dose, transparent (type I glass), 2 ml, with a rubber stopper and a gray plastic flip-off cap with an aluminum seal.
  • A multi-dose vial of 6 doses, transparent (type I glass), 2 ml, with a rubber stopper and a gray plastic flip-off cap with an aluminum seal.

Size of the single-dose vial container: 10 vials.

Sizes of the multi-dose vial container: 10 vials or 195 vials. Only some package sizes may be marketed.

Marketing Authorization Holder

BioNTech Manufacturing GmbH An der Goldgrube 12

55131 Mainz Germany

Phone: +49 6131 9084-0

Fax: +49 6131 9084-2121

[email protected]

Manufacturers

BioNTech Manufacturing GmbH

Kupferbergterrasse 17-19

55116 Mainz

Germany

Pfizer Manufacturing Belgium NV

Rijksweg 12

2870 Puurs

Belgium

You can request more information about this medicinal product by contacting the local representative of the marketing authorization holder.

België/Belgique/Belgien

Luxembourg/Luxemburg

Pfizer S.A./N.V.

Tél/Tel: +32 (0)2 554 62 11

Lietuva

Pfizer Luxembourg SARL filialas Lietuvoje

Tel. +370 52 51 4000

Text in a foreign language with Pfizer Luxembourg SARL contact information and phone number

Magyarország

Pfizer Kft

Tel: +36 1 488 3700

Ceská republika

Pfizer, spol. s r.o.

Tel: +420 283 004 111

Malta

Vivian Corporation Ltd.

Tel: +35621 344610

Danmark

Pfizer ApS

Tlf: +45 44 201 100

Norge

Pfizer AS

Tlf: +47 67 526 100

Deutschland

BioNTech Manufacturing GmbH

Tel: +49 6131 90840

Nederland

Pfizer BV

Tel: +31 (0)10 406 43 01

Eesti

Pfizer Luxembourg SARL Eesti filiaal

Tel: +372 666 7500

Österreich

Pfizer Corporation Austria Ges.m.b.H

Tel: +43 (0)1 521 15-0

Ελλάδα

Pfizer Ελλάς A.E.

Τηλ.: +30 210 6785 800

Polska

Pfizer Polska Sp. z o.o.

Tel.: +48 22 335 61 00

España

Pfizer, S.L.

Tel:+ 34914909900

Portugal

Laboratórios Pfizer, Lda.

Tel: +351 21 423 5500

France

Pfizer

Tél +33 1 58 07 34 40

România

Pfizer Romania S.R.L

Tel: +40 (0) 21 207 28 00

Hrvatska

Pfizer Croatia d.o.o.

Tel: +385 1 3908 777

Slovenija

Pfizer Luxembourg SARL

Pfizer, podružnica za svetovanje s podrocja

farmacevtske dejavnosti, Ljubljana

Tel.: +386 (0) 1 52 11 400

Ireland

Pfizer Healthcare Ireland

Tel: 1800 633 363 (toll free)

+44 (0)1304 616161

Slovenská republika

Pfizer Luxembourg SARL,

organizacná zložka

Tel: +421 2 3355 5500

Ísland

Icepharma hf

Simi: +354 540 8000

Suomi/Finland

Pfizer Oy

Puh/Tel: +358 (0)9 430 040

Italia

Pfizer S.r.l.

Tel: +39 06 33 18 21

Sverige

Pfizer AB

Tel: +46 (0)8 550 520 00

Κύπρος

Pfizer Ελλάς Α.Ε. (Cyprus Branch)

Τηλ: +357 22 817690

United Kingdom (Northern Ireland)

Pfizer Limited

Tel: +44 (0) 1304 616161

Latvija

Pfizer Luxembourg SARL filiale Latvija

Tel.: +371 670 35 775

Date of the Last Revision of this Leaflet: {MM/YYYY}

Scan the code with a mobile device to obtain the leaflet in different languages.

Square QR code with black and white modules on a white background

URL: www.comirnatyglobal.com

Detailed information on this medicinal product is available on the European Medicines Agency website: http://www.ema.europa.eu.

The leaflet for this product is available in all languages of the European Union/European Economic Area on the European Medicines Agency website.

This information is intended for healthcare professionals only:

The dose of Comirnaty Original/Omicron BA.4-5 is 0.3 ml administered intramuscularly.

There should be an interval of at least 3 months between the administration of Comirnaty Original/Omicron BA.4-5 and the last previous dose of a COVID-19 vaccine.

Comirnaty Original/Omicron BA.4-5 is only indicated in individuals who have previously received at least one primary vaccination schedule against COVID-19.

Traceability

In order to improve the traceability of biological medicinal products, the name and batch number of the administered product must be clearly recorded.

Handling Instructions

Comirnaty Original/Omicron BA.4-5 (15/15 micrograms)/dose must be prepared by a healthcare professional using aseptic technique to ensure the sterility of the prepared dispersion.

INSTRUCTIONS APPLICABLE TO BOTH SINGLE-DOSE AND MULTI-DOSE VIALS

VERIFICATION OF COMIRNATY ORIGINAL/OMICRON BA.4-5 (15/15 MICROGRAMS)/DOSE DISPERSION FOR INJECTION (PERSONS 12 YEARS OF AGE AND OLDER)

Vial of medicine with gray label and arrows pointing to details such as 'Gray cap' and 'Comirnaty Original/Omicron BA.4-5 Do not dilute'

  • Check that the vial has a gray plastic cap and a gray border around the label and that the product name is Comirnaty Original/Omicron BA.4-5 (15/15 micrograms)/dose dispersion for injection.
  • Check if the vial is a single-dose or multi-dose vial and follow the applicable handling instructions below.
  • If the vial has a gray plastic cap and a gray border and the product name is Comirnaty 30 micrograms/dose dispersion for injection or Comirnaty Original/Omicron BA.1 (15/15 micrograms)/dose dispersion for injection, consult the summary of product characteristics or package leaflet for that formulation.
  • If the vial has a purple plastic cap, consult the summary of product characteristics or package leaflet for Comirnaty 30 micrograms/dose concentrate for dispersion for injection.
  • If the vial has an orange plastic cap, consult the summary of product characteristics or package leaflet for Comirnaty 10 micrograms/dose concentrate for dispersion for injection or Comirnaty Original/Omicron BA.4-5 (5/5 micrograms)/dose concentrate for dispersion for injection.
  • If the vial has a maroon plastic cap, consult the summary of product characteristics or package leaflet for Comirnaty 3 micrograms/dose concentrate for dispersion for injection.

HANDLING BEFORE USE OF COMIRNATY ORIGINAL/OMICRON BA.4-5 (15/15 MICROGRAMS)/DOSE DISPERSION FOR INJECTION (PERSONS 12 YEARS OF AGE AND OLDER)

White refrigerator with snowflake and transparent vial of medicine with gray cap and text indicating storage between 2 and 8 degrees Celsius

  • If the single-dose or multi-dose vial is stored frozen, it must be thawed before use. Frozen vials should be transferred to a refrigerated area between 2 °C and 8 °C to thaw. Ensure that the vials are completely thawed before using them.
    • Single-dose vials: a package of 10 single-dose vials may take 2 hours to thaw.
    • Multi-dose vials: a package of 10 multi-dose vials may take 6 hours to thaw.
  • When transferring the vials to storage at 2 °C to 8 °C, update the expiration date on the carton.
  • Unopened vials can be stored for a maximum of 10 weeks at 2 °C to 8 °C; do not exceed the printed expiration date (EXP).
  • Alternatively, individual frozen vials can be thawed for 30 minutes at temperatures up to 30 °C.
  • Before use, unopened vials can be stored for a maximum of 12 hours at temperatures up to 30 °C. Thawed vials can be handled in ambient light conditions.

Gloved hand holding vials and syringe adapters with curved arrows indicating rotation for connection

Gently 10 times

  • Gently mix the vials by inverting them 10 times before use. Do not shake them.
  • Before mixing, the frozen dispersion may contain amorphous particles of a color between white and off-white.
  • After mixing, the vaccine should have the appearance of a dispersion between white and off-white without visible particles. Do not use the vaccine if it contains visible particles or a color change.

PREPARATION OF INDIVIDUAL 0.3 ML DOSES OF COMIRNATY ORIGINAL/OMICRON BA.4-5 (15/15 MICROGRAMS)/DOSE DISPERSION FOR INJECTION (PERSONS 12 YEARS OF AGE AND OLDER)

Gloved hand holding syringe filling with liquid from vial and detail of graduated scale showing 0.3 ml dose

0.3 ml of vaccine

Single-dose vials

  • Withdraw a single 0.3 ml dose of vaccine.
  • Discard the vial and any remaining volume.

Multi-dose vials

  • Multi-dose vials contain 6 doses of 0.3 ml each.
  • Using aseptic technique, clean the vial stopper with a single-use antiseptic swab.
  • Withdraw 0.3 ml of Comirnaty Original/Omicron BA.4-5.

To withdraw 6 doses from the same vial, use syringes and/or needles with a low dead volume. The combination of syringe and needle with a low dead volume should have a dead volume of 35 microliters or less.

If conventional syringes and needles are used, there may not be sufficient volume to withdraw a sixth dose from the same vial.

  • Each dose must contain 0.3 ml of vaccine.
  • If the remaining volume of vaccine in the vial is not sufficient to provide a full 0.3 ml dose, discard the vial and any remaining volume.
  • Record the time and date on the vial. Discard the vaccine that has not been used 12 hours after the first puncture.

Disposal

Disposal of unused medicinal products and all materials that have come into contact with them should be carried out in accordance with local regulations.

Online doctors for COMIRNATY ORIGINAL/OMICRON BA.4-5 (15/15 MICROGRAMS)/DISPERSIBLE INJECTABLE DOSE

Discuss questions about COMIRNATY ORIGINAL/OMICRON BA.4-5 (15/15 MICROGRAMS)/DISPERSIBLE INJECTABLE DOSE, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (183)
Doctor

Yevgen Yakovenko

General surgery 12 years exp.

Dr. Yevgen Yakovenko is a licensed surgeon and general practitioner in Spain and Germany. He specialises in general, paediatric, and oncological surgery, internal medicine, and pain management. He offers online consultations for adults and children, combining surgical precision with therapeutic support. Dr Yakovenko works with patients across different countries and provides care in Ukrainian, Russian, English, and Spanish.

Areas of medical expertise:

  • Acute and chronic pain: headaches, muscle and joint pain, back pain, abdominal pain, postoperative pain. Identifying the cause, selecting treatment, and creating a care plan.
  • Internal medicine: heart, lungs, gastrointestinal tract, urinary system. Management of chronic conditions, symptom control, second opinions.
  • Pre- and postoperative care: risk assessment, decision-making support, follow-up after surgery, rehabilitation strategies.
  • General and paediatric surgery: hernias, appendicitis, congenital conditions, both planned and urgent surgeries.
  • Injuries and trauma: bruises, fractures, sprains, soft tissue damage, wound care, dressing, referral when in-person care is required.
  • Oncological surgery: diagnosis review, treatment planning, and long-term follow-up.
  • Obesity treatment and weight management: a medical approach to weight loss, including assessment of underlying causes, evaluation of comorbidities, development of a personalised plan (nutrition, physical activity, pharmacotherapy if needed), and ongoing progress monitoring.
  • Imaging interpretation: analysis of ultrasound, CT, MRI, and X-ray results, surgical planning based on imaging data.
  • Second opinions and medical navigation: clarifying diagnoses, reviewing current treatment plans, helping patients choose the best course of action.

Experience and qualifications:

  • 12+ years of clinical experience in university hospitals in Germany and Spain.
  • International education: Ukraine – Germany – Spain.
  • Member of the German Society of Surgeons (BDC).
  • Certified in radiological diagnostics and robotic surgery.
  • Active participant in international medical conferences and research.

Dr Yakovenko explains complex topics in a clear, accessible way. He works collaboratively with patients to analyse health issues and make evidence-based decisions. His approach is grounded in clinical excellence, scientific accuracy, and respect for each individual.

If you are unsure about a diagnosis, preparing for surgery, or want to discuss your test results – Dr Yakovenko will help you evaluate your options and move forward with confidence.

Camera Book a video appointment
€50
0.0 (17)
Doctor

Daniel Cichi

Family medicine 24 years exp.

Dr Daniel Cichi is a family medicine doctor with over 20 years of clinical experience. He provides online consultations for adults, supporting patients with acute symptoms, chronic conditions, and everyday health concerns that require timely medical guidance. His background includes work in emergency care, ambulance services, and family medicine, which allows him to assess symptoms quickly, identify warning signs, and help patients choose the safest next steps – whether that means home care, treatment adjustment, or in-person evaluation. Patients commonly consult Dr Daniel Cichi for: 

  • acute symptoms: fever, infections, flu-like illness, cough, sore throat, shortness of breath;
  • chest discomfort, palpitations, dizziness, fatigue, and blood pressure concerns;
  • digestive problems: abdominal pain, nausea, diarrhoea, constipation, reflux;
  • sexually transmitted infections, erectile dysfunction;
  • muscle, joint, and back pain, minor injuries, post-traumatic symptoms;
  • chronic conditions: hypertension, diabetes, high cholesterol, thyroid disorders, weight loss, hair loss;
  • review and interpretation of lab tests, imaging reports, and medical documents;
  • medication review and treatment adjustment;
  • medical advice while travelling or living abroad;
  • second opinions and guidance on whether in-person care is needed.

Dr Cichi’s consultations are structured and practical. He focuses on clear explanations, risk assessment, and actionable recommendations, helping patients understand their symptoms and make informed decisions about their health.

Camera Book a video appointment
€55
5.0 (40)
Doctor

Lina Travkina

Family medicine 13 years exp.

Dr. Lina Travkina is a licensed family and preventive medicine doctor based in Italy. She provides online consultations for adults and children, supporting patients across all stages of care – from acute symptom management to long-term health monitoring and prevention.

Areas of medical care include:

  • Respiratory conditions: colds, flu, acute and chronic bronchitis, mild to moderate pneumonia, bronchial asthma.
  • ENT and eye conditions: sinusitis, tonsillitis, pharyngitis, otitis, infectious and allergic conjunctivitis.
  • Digestive issues: gastritis, acid reflux (GERD), IBS, dyspepsia, bloating, constipation, diarrhoea, functional bowel symptoms, intestinal infections.
  • Urological and infectious diseases: acute and recurrent cystitis, bladder and kidney infections, prevention of recurrent UTIs, asymptomatic bacteriuria.
  • Chronic conditions: hypertension, diabetes, hypercholesterolemia, metabolic syndrome, thyroid disorders, excess weight.
  • Neurological and general symptoms: headache, migraine, dizziness, fatigue, sleep disturbances, reduced concentration, anxiety, asthenia.
  • Chronic pain support: back, neck, joint, and muscle pain, tension syndromes, pain associated with osteochondrosis and chronic conditions.

Additional care areas:

  • Preventive consultations and check-up planning.
  • Medical advice and follow-up consultations.
  • Test interpretation and diagnostic guidance.
  • Structured support for undiagnosed complaints.
  • Second opinion on diagnoses and treatment plans.
  • Nutritional and lifestyle support for vitamin deficiencies, anaemia, metabolic issues.
  • Post-operative recovery support and pain management.
  • Preconception counselling and postpartum support.
  • Immunity support and strategies to reduce frequency of infections.

Dr. Travkina combines evidence-based medicine with an attentive, personalised approach. Her consultations focus not only on treatment, but also on prevention, recovery, and long-term wellbeing.

If during the consultation it becomes clear that your case requires in-person assessment or specialised care outside of her scope, the session will be terminated and the payment fully refunded.

Camera Book a video appointment
€70
0.0 (0)
Doctor

Hocine Lokchiri

General medicine 21 years exp.

Dr. Hocine Lokchiri is a French consultant with over 20 years of experience in General and Emergency Medicine. He works with adults and children, helping patients with urgent symptoms, infections, sudden health changes and everyday medical concerns that require timely evaluation. His background includes clinical practice in France, Switzerland and the United Arab Emirates, which allows him to navigate different healthcare systems and manage a wide range of conditions with confidence. Patients value his calm, structured approach, clear explanations and evidence-based decision-making.

Online consultations with Dr. Lokchiri are suitable for many situations when someone needs quick medical guidance, reassurance or a clear next step. Common reasons for booking include:

  • fever, chills, fatigue and viral symptoms
  • cough, sore throat, nasal congestion, breathing discomfort
  • bronchitis and mild asthma flare-ups
  • nausea, diarrhoea, abdominal pain, digestive infections
  • rashes, allergic reactions, redness, insect bites
  • muscle or joint pain, mild injuries, sprains
  • headache, dizziness, migraine symptoms
  • stress-related symptoms, sleep disturbances
  • questions about test results and treatment plans
  • management of chronic conditions in stable phases
Many patients reach out when symptoms appear suddenly and cause concern, when a child becomes unwell unexpectedly, when a rash changes or spreads, or when it’s unclear whether an in-person examination is necessary. His emergency medicine background is particularly valuable online, helping patients understand risk levels, identify warning signs and choose safe next steps.

Some situations are not suitable for online care. If a patient has loss of consciousness, severe chest pain, uncontrolled bleeding, seizures, major trauma or symptoms suggesting a stroke or heart attack, he will advise seeking immediate local emergency services. This improves safety and ensures patients receive the right level of care.

Dr. Lokchiri’s professional training includes:

  • Advanced Trauma Life Support (ATLS)
  • Basic and Advanced Cardiac Life Support (BLS/ACLS)
  • Pediatric Advanced Life Support (PALS)
  • Prehospital Trauma Life Support (PHTLS)
  • eFAST and critical care transthoracic echocardiography
  • aviation medicine
He is an active member of several professional organisations, including the French Society of Emergency Medicine (SFMU), the French Association for Emergency Physicians (AMUF) and the Swiss Society of Emergency and Rescue Medicine (SGNOR). In consultations, he works with clarity and precision, helping patients understand their symptoms, possible risks and the safest treatment options.
Camera Book a video appointment
€58
5.0 (5)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques. For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance. Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults. In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions. Patients commonly seek his care for: 

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns

Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.

Camera Book a video appointment
€80
5.0 (1055)
Doctor

Andrei Popov

General medicine 7 years exp.

Dr. Andrei Popov is a family physician with specialized training in the management of chronic pain. He provides video consultations for adults in Spain and across Europe: whether you have been living with pain for months that no one has been able to properly explain, or you need to resolve a health issue without waiting weeks for an appointment.

His approach is clear: to listen, organize your case, and provide you with a practical roadmap based on evidence-based medicine and adapted to your medical history and personal needs.

Pain: how he can help

  • Chronic pain (more than 3 months
  • Migraine and recurrent or high-intensity headaches
  •  Neck, lower back, back and joint pain
  •  Post-traumatic pain after injuries or surgeries
  •  Pain of neurological origin: neuralgia, neuropathic pain, fibromyalgia

General medicine

  • Frequent respiratory infections (cold, flu, persistent cough)
  • Hypertension, diabetes and metabolic disorders
  • Review of laboratory tests and MRI/CT reports (explained in clear language)
  • Preventive medicine and health monitoring
  • Second opinions and treatment adjustments (when clinically appropriate)

What the consultation is like
 Each session lasts up to 30 minutes. We review symptoms, medical history, medications and any tests you provide, and you finish the consultation with a clear treatment plan, defined next steps, and criteria to understand when follow-up may be needed. If warning signs are detected, he will clearly advise whether you need in-person care or urgent medical attention.

Camera Book a video appointment
€80

Frequently Asked Questions

Is a prescription required for COMIRNATY ORIGINAL/OMICRON BA.4-5 (15/15 MICROGRAMS)/DISPERSIBLE INJECTABLE DOSE?
COMIRNATY ORIGINAL/OMICRON BA.4-5 (15/15 MICROGRAMS)/DISPERSIBLE INJECTABLE DOSE requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in COMIRNATY ORIGINAL/OMICRON BA.4-5 (15/15 MICROGRAMS)/DISPERSIBLE INJECTABLE DOSE?
The active ingredient in COMIRNATY ORIGINAL/OMICRON BA.4-5 (15/15 MICROGRAMS)/DISPERSIBLE INJECTABLE DOSE is covid-19, RNA-based vaccine. This information helps identify medicines with the same composition but different brand names.
Who manufactures COMIRNATY ORIGINAL/OMICRON BA.4-5 (15/15 MICROGRAMS)/DISPERSIBLE INJECTABLE DOSE?
COMIRNATY ORIGINAL/OMICRON BA.4-5 (15/15 MICROGRAMS)/DISPERSIBLE INJECTABLE DOSE is manufactured by Biontech Manufacturing Gmbh. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of COMIRNATY ORIGINAL/OMICRON BA.4-5 (15/15 MICROGRAMS)/DISPERSIBLE INJECTABLE DOSE online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether COMIRNATY ORIGINAL/OMICRON BA.4-5 (15/15 MICROGRAMS)/DISPERSIBLE INJECTABLE DOSE is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to COMIRNATY ORIGINAL/OMICRON BA.4-5 (15/15 MICROGRAMS)/DISPERSIBLE INJECTABLE DOSE?
Other medicines with the same active substance (covid-19, RNA-based vaccine) include COMIRNATY 10 micrograms/dose injectable dispersion concentrate, COMIRNATY 3 micrograms/dose injectable dispersion concentrate, COMIRNATY 30 micrograms/dose Injectable Dispersion. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media